Fulvestrant - Wikipedia

Fulvestrant, sold under the brand name Faslodex among others, is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal ...

Faslodex® - min.medicin.dk – information om medicin

Injektionsvæske, opløsning. 1 ml indeholder 50 mg fulvestrant. ...

Fulvestrant

Min.medicin.dk er en hjemmeside om medicin, sygdomme, undersøgelser og behandling skrevet i et let tilgængeligt sprog. Oplysningerne er målrettet dig, der er ...

FASLODEX® (fulvestrant) Injection 500 mg | Metastatic ...

IMPORTANT SAFETY INFORMATION. You should not receive FASLODEX if you have had an allergic reaction to fulvestrant or any of the ingredients in FASLODEX.

Faslodex® - pro.medicin.dk – information om medicin

Fulvestrant bør kun anvendes, når behandlingen forestås af læger med særligt kendskab til maligne lidelser og deres behandling. ...

Fulvestrant - National Cancer Institute - Comprehensive ...

This page contains brief information about fulvestrant and a collection of links to more information about the use of this drug, research results, and ongoing ...

Fulvestrant kan være på vej til standardbehandling

Fulvestrant (Faslodex) øger den progressionsfrie overlevelse hos kvinder med hormon-receptor-positiv fremskreden brystkræft. Det viser et fase lll-studie, der blev ...

Fulvestrant: Indications, Side Effects, Warnings - Drugs.com

Easy-to-read patient leaflet for Fulvestrant. Includes indications, proper use, special instructions, precautions, and possible side effects.

European Medicines Agency - Find medicine - Fulvestrant Mylan

This is a summary of the European public assessment report (EPAR) for Fulvestrant Mylan. It explains how the Agency assessed the medicine to recommend its ...

European Medicines Agency - Find medicine - Faslodex

The active substance in Faslodex, fulvestrant, is an anti-oestrogen. It blocks the receptors for oestrogen on cells and causes the number of oestrogen receptors to fall.